<DOC>
	<DOCNO>NCT02357615</DOCNO>
	<brief_summary>The purpose study compare nifedipine controlled-release ( CR ) tablet ( Xin Ran ) nifedipine controlled-release tablet ( Adalat）in treatment Early Morning Blood Pressure Central Arterial Pressure .</brief_summary>
	<brief_title>Efficacy Study Nifedipine Controlled-Release Tablets ( Xin Ran ) Treat Early Morning Blood Pressure Central Arterial Pressure</brief_title>
	<detailed_description />
	<mesh_term>Nifedipine</mesh_term>
	<criteria>Voluntarily participate must sign informed consent form Mild moderate essential hypertension ( SBP 140179 mmHg and/or DBP 90109 mmHg ) The mean morning blood press one week ＞135/85 mmHg Secondary hypertension malignant hypertension Pregnant nursing woman , patient guarantee take effective contraception measure Baseline SBP≥180 mmHg DBP≥110 mmHg , patient cerebral , cardiac renal complication Have follow complication : cerebrovascular accident within 6 month , myocardial infarction cardiac failure , macroaneurysm dissect aneurysm , definite angina , AV block grade 2 high , sick sinus syndrome , atrial fibrillation malignant arrhythmia Clinical significant disease heart , lung , liver , kidney hematologic system malignant tumor , HIV infection , uncontrolled diabetes ( fast blood glucose ≥7.0 mmol/L , 2hour postprandial blood glucose ≥7.8 mmol/L ) Kock pouch Sever gastrointestinal stenosis Abnormal laboratory value clinical significance , include serum potassium &lt; 3.5 &gt; 5.5 mmol/L , glutamicpyruvic transaminase ( ALT ) glutamic oxalacetic transaminase ( AST ) &gt; 2fold upper limit normal ( ULN ) , Cr &gt; ULN Gastrointestinal abnormality surgery may interfere drug absorption Hyperthyroidism hypothyroidism Allergic ingredient metabolite investigational drug drug similar structure Psychological disease , acrasia , express explicitly Patients whose mood may affect variation blood pressure , turn increase blood pressure Anxiety disorder , depression follow study protocol BMI &gt; 30 Night shift , irregular sleep pattern insomnia participate clinical trial within 3 month condition investigator consider unsuitable participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>